Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Unknown 2Recruiting 2Not yet recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Vinorelbine 3Capecitabine 2ribociclib 1pyrotinib 1Trastuzumab 1Lapatinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
HER2-positive Advanced Breast Cancer × Clear all
NCT07047365 2026-02-02

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
416 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT06481956 2024-07-01

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

Zhejiang Cancer Hospital

Phase 2 Enrolling by invitation
40 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT05901935 2023-06-13

DP303c in Patients With HER2-positive Advanced Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
420 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT05856383 2023-05-12

HER2-VIP

Zhejiang Cancer Hospital

Recruiting
100 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04903652 2022-04-07

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Completed
30 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04963608 2021-07-15

RWS of Inetetamab HER2 Positive Advanced Breast Cancer

Shandong Cancer Hospital and Institute

Unknown
100 enrolled
Breast

HER2-positive Advanced Breast Cancer

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Bio-Thera Solutions

Phase 3 Unknown
410 enrolled
Breast

HER2-positive Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡